Showing results (461-470 of 3,353) with videos related to

Sort By:
Pageof 336
The Lancet. Oncology|July 11, 2025
Derivation and validation of the AJCC9V pathological stage classification for HPV-positive oropharyngeal carcinoma: a multicentre registry analysisAllen S Ho, Shao Hui Huang, Brian O'Sullivan, et al.
The Lancet. Oncology|June 5, 2025
Zanidatamab plus chemotherapy as first-line treatment for patients with HER2-positive advanced gastro-oesophageal adenocarcinoma: primary results of a multicentre, single-arm, phase 2 studyElena Elimova, Jaffer Ajani, Howard Burris, et al.
The Lancet. Oncology|June 14, 2025
Partial-breast radiotherapy after breast conservation surgery for women with early breast cancer (UK IMPORT LOW): 10-year outcomes from a multicentre, open-label, randomised, controlled, phase 3, non-inferiority trialAnna M Kirby, Laura Finneran, Clare L Griffin, et al.
The Lancet. Oncology|June 6, 2025
Benchmarking infrastructure for cancer control in Commonwealth countries: a population-based observational studyChe L Reddy, Cecilia Sousa, Rifat Atun
The Lancet. Oncology|November 13, 2025
Effectiveness of NELSON versus PLCOm2012 lung cancer screening eligibility criteria in Germany (HANSE): a prospective cohort studyJens Vogel-Claussen, Benjamin-Alexander Bollmann, Katharina May, et al.
The Lancet. Oncology|October 2, 2025
Long-term overall survival with dual CTLA-4 and PD-L1 or PD-1 blockade and biomarker-based subgroup analyses in patients with advanced non-small-cell lung cancer: a systematic review and reconstructed individual patient data meta-analysisAlessandro Di Federico, Sara Stumpo, Francesco Mantuano, et al.
The Lancet. Oncology|October 2, 2025
Genetic modification of the AJCC classification of papillary thyroid cancer: an international, multicentre, retrospective cohort studyMingzhao Xing, Shuhuang Lin, Aarti Mathur, et al.
The Lancet. Oncology|October 2, 2025
Safety and efficacy of a dexamethasone-sparing regimen with daratumumab and lenalidomide in patients with frailty and newly diagnosed multiple myeloma (IFM2017-03): a phase 3, open-label, multicentre, randomised, controlled trialSalomon Manier, Jérôme Lambert, Cyrille Hulin, et al.
The Lancet. Oncology|October 2, 2025
Challenges for Chinese innovative cancer drugs in going global: insights from multiregional clinical trialsXin Du, Zhong Zhao, Xiaoqian Sun, et al.
The Lancet. Oncology|July 10, 2025
Metformin for patients with metastatic prostate cancer starting androgen deprivation therapy: a randomised phase 3 trial of the STAMPEDE platform protocolSilke Gillessen, Laura Murphy, Nicholas D James, et al.
Pageof 336